Jafron Biomedical Co.,Ltd. Stock

Equities

300529

CNE100002995

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
22.16 CNY -1.51% Intraday chart for Jafron Biomedical Co.,Ltd. -3.19% -0.31%
Sales 2023 * 2B 277M Sales 2024 * 2.52B 348M Capitalization 17.7B 2.44B
Net income 2023 * 591M 81.63M Net income 2024 * 775M 107M EV / Sales 2023 * 8.83 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 7.03 x
P/E ratio 2023 *
30.4 x
P/E ratio 2024 *
23.2 x
Employees 3,003
Yield 2023 *
-
Yield 2024 *
-
Free-Float 47.08%
More Fundamentals * Assessed data
Dynamic Chart
Tranche Update on Jafron Biomedical Co.,Ltd.'s Equity Buyback Plan announced on July 17, 2023. CI
Tranche Update on Jafron Biomedical Co.,Ltd.'s Equity Buyback Plan announced on July 17, 2023. CI
Jafron Biomedical Co.,Ltd.'s Equity Buyback announced on July 17, 2023, has closed with 24,242,904 shares, representing 3% for CNY 500 million. CI
Tranche Update on Jafron Biomedical Co.,Ltd.'s Equity Buyback Plan announced on July 17, 2023. CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Zhuhai Jianfu Pharmaceutical Co., Ltd. announced that it expects to receive CNY 15 million in funding from Jafron Biomedical Co.,Ltd. CI
Tranche Update on Jafron Biomedical Co.,Ltd.'s Equity Buyback Plan announced on July 17, 2023. CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Jafron Biomedical Co.,Ltd. announces an Equity Buyback for CNY 500 million worth of its shares. CI
Jafron Biomedical Co.,Ltd. authorizes a Buyback Plan. CI
Jafron Biomedical Co.,Ltd. Announces Cash Dividend on A Shares for the Year 2022, Payable on 31 May 2023 CI
Jafron Biomedical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Jafron Biomedical Co.,Ltd. Approves the Cash Dividend for 2022 CI
Jafron Biomedical Co.,Ltd. Approves Director Elections CI
Jafron Biomedical Co.,Ltd. Announces Profit Distribution Proposal for 2022 CI
More news
1 day-1.51%
1 week-3.19%
Current month-0.31%
1 month-6.10%
3 months+14.70%
6 months+3.07%
Current year-0.31%
More quotes
1 week
22.03
Extreme 22.03
23.77
1 month
21.75
Extreme 21.75
24.93
Current year
15.88
Extreme 15.88
24.93
1 year
15.88
Extreme 15.88
31.33
3 years
15.88
Extreme 15.88
103.00
5 years
15.88
Extreme 15.88
103.00
10 years
6.82
Extreme 6.8211
103.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 98-12-31
Director/Board Member 45 12-12-31
Director/Board Member 54 09-12-31
Members of the board TitleAgeSince
Director/Board Member 62 23-04-20
Director/Board Member 51 23-04-20
Chief Executive Officer 54 98-12-31
More insiders
Date Price Change Volume
24-04-19 22.16 -1.51% 5,022,557
24-04-18 22.5 -1.53% 4,277,793
24-04-17 22.85 -0.22% 6,771,052
24-04-16 22.9 -0.87% 5,694,978
24-04-15 23.1 +0.92% 6,488,661

End-of-day quote Shenzhen S.E., April 18, 2024

More quotes
Jafron Biomedical Co.,Ltd. is a China-based company principally engaged in the research, design, manufacture and distribute of biological materials and medical equipment. The Company’s products include disposable hemoperfusion devices, hemoperfusion machine, disposable bilirubin adsorbers, DX-10 blood purification machine, suture needle, as well as resins bandage, among others. The Company’s products are applied in uremia, poisoning, severe liver diseases, autoimmune diseases, as well as multisystem organ failure, among others. The Company’s products are applied in 31 provinces, more than 3000 hospitals in China.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
22.16 CNY
Average target price
26.62 CNY
Spread / Average Target
+20.10%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300529 Stock